<DOC>
	<DOCNO>NCT02426216</DOCNO>
	<brief_summary>This prospectively investigate whether chemopreventive agent , MCS , may favorably alter biomarker expression , whether serum carotenoid level associate biomarkers level , whether alteration biomarker expression may reflect cancer risk show cancer incidence end clinical trial .</brief_summary>
	<brief_title>Molecular Effects Multi-carotenoids ( MCS ) New Agent Prostate Cancer Chemoprevention</brief_title>
	<detailed_description>Many epidemiological study show nutrient element tomato plant , include lycopene multi-carotenoids , may reduce risk prostate cancer , especially lethal cancer . Studies also show multi-carotenoids may reduce serum PSA level prostate cancer patient . MCS patent , multi-carotenoids-rich , purely botanic agent . The investigator ' previous Phase II III clinical trial ( US FDA TFDA , 600 subject , study finish , data analysis ) show MCS-related serious adverse event ( SAE ) . MCS may relieve urinary symptom men BPH PSA reduce men elevate PSA . So , investigator initiate large multi-center phase II randomize study ( MCS-8 , N=702 ) Taiwan , study MCS reduce risk prostate cancer . High risk patient assign take oral daily 30 , 15 , 0 ( placebo ) mg MCS ( 1:1:1 ) . The investigator compare cumulative prostate cancer incidence among group change baseline serum carotenoid level . ( MCS-8-TWN-II Clinicaltrials.gov NCT02042807 )</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Carotenoids</mesh_term>
	<criteria>Inclusion criterion : 1 . Subject MCS8 study inclusion criterion MCS8 study 1. highrisk subject prostate cancer . 2 . Male subject age 50 75 year old . 3 . No active urinary tract infection ( UTI ) bacterial prostatitis . 4 . Subject able understand willing comply study procedure sign informed consent form ( ICF ) . exclusion criterion MCS8 study 1 . Subjects ' elevate PSA deem investigator solely inflammation infection prostate . 2 . Subjects take longterm hormonal agent may affect normal physiology sex hormone function . 3 . Subjects PSA &gt; 10.0 ng/ml . 4 . Subjects history prostate cancer . 5 . Subjects currently take plan take oral bile acid sequestrants . 6 . Subjects malabsorption condition . 7 . Subject participate another investigational agent study past 30 day plan study period . 8 . Subjects consider ineligible study judge investigator . 9 . Other malignancy except nonmelanoma skin cancer . 2 . Subject eligible MCS8 study sign MCS8 study . Exclusion criterion : Subject able understand willing comply study procedure sign informed consent form ( ICF ) . Note : ( MCS8TWNII Clinicaltrials.gov NCT02042807 )</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>chemoprevention</keyword>
	<keyword>biomarker</keyword>
</DOC>